SHIRE HOLDINGS AG has a total of 56 patent applications. Its first patent ever was published in 2000. It filed its patents most often in Australia, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals, medical technology and organic fine chemistry are PHARMAGENESIS INC, CELL THERAPEUTICS EUROPE SRL and RSPR PHARMA AB.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 7 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | Canada | 4 | |
#4 | United States | 4 | |
#5 | Brazil | 3 | |
#6 | Israel | 3 | |
#7 | Republic of Korea | 3 | |
#8 | Mexico | 3 | |
#9 | Norway | 3 | |
#10 | South Africa | 3 | |
#11 | China | 2 | |
#12 | EAPO (Eurasian Patent Organization) | 2 | |
#13 | Hong Kong | 2 | |
#14 | New Zealand | 2 | |
#15 | Singapore | 2 | |
#16 | African Regional Industrial Property Organization | 1 | |
#17 | Colombia | 1 | |
#18 | United Kingdom | 1 | |
#19 | Croatia | 1 | |
#20 | Japan | 1 | |
#21 | Poland | 1 | |
#22 | Serbia | 1 | |
#23 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Medical technology | |
#3 | Organic fine chemistry | |
#4 | Machines |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Medical purpose containers | |
#4 | Heterocyclic compounds | |
#5 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Franklin Richard | 31 |
#2 | Trespidi Laura Anna | 9 |
#3 | Haslam Robert Paul | 8 |
#4 | Gaitonde Michael David | 7 |
#5 | Atherton Nigel Derek | 6 |
#6 | Ferdinando Josephine Christine | 5 |
#7 | Totten Joseph Wilson | 4 |
#8 | Totten Joseph W | 3 |
#9 | Richard Franklin | 3 |
#10 | Ferdinando Josesphine Christine | 2 |
Publication | Filing date | Title |
---|---|---|
AU2007200221A1 | Use of lanthanum compounds for the treatment of bone diseases | |
US2006030574A1 | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | |
US2006052601A1 | Quinazoline derivatives and their use in the treatment of thrombocythemia | |
MXPA06002257A | Pharmaceutical formulation comprising lanthanum compounds. | |
SG153661A1 | Formulation and methods for the treatment of thrombocythemia | |
GB0015745D0 | Treatment of bone diseases |